Clinical—Alimentary TractDirect Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults
Section snippets
Study Design and Data Source
In this cross-sectional study, we analyzed the medical, surgical, and pharmaceutical insurance claims contained in the PharMetrics Patient-Centric Database (IMS Health, Watertown, MA) for the period from January 1, 2003, to December 31, 2004. This longitudinal, patient-level database has been used in previous epidemiologic studies of IBD11 and at the time of this study included claims from 87 health plans in 33 states. The included plans capture a geographically diverse sample of commercially
Study Population
Our study population included 9056 patients with CD and their 24,829 matched controls and 10,364 patients with UC and their 28,160 matched controls (Table 1). The mean age of patients with CD and patients with UC was 42 years (SD, 13 years) and 45 years (SD, 12 years), respectively. Fifty-six percent of patients with CD and 53% of patients with UC were women. Each of the 4 major US census regions was adequately represented in our patient population. There were no statistically significant
Discussion
This study provides an updated estimate of the treatment costs of CD and UC in the United States, a necessary step in understanding the overall burden of IBD in this country. In our sample of nearly 20,000 US children and adults with IBD, we found that the mean treatment costs for CD were $8265 per year and for UC were $5066 per year. As with many illnesses, a disproportionate amount of the overall societal costs resulted from the individuals with the highest resource utilization, as indicated
References (22)
Factors accounting for the rise in health-care spending in the United States: the role of rising disease prevalence and treatment intensity
Public Health
(2006)- et al.
Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey
Am J Gastroenterol
(2003) - et al.
Quality of life of patients with ulcerative colitis preoperatively and postoperatively
Gastroenterology
(1991) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences
Gastroenterology
(2004)The burden of inflammatory bowel disease in the United States: a moving target?
Clin Gastroenterol Hepatol
(2007)- et al.
The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States
Clin Gastroenterol Hepatol
(2007) - et al.
Annual cost of care for Crohn's disease: a payor perspective
Am J Gastroenterol
(2000) - et al.
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease
Gastroenterology
(2005) - et al.
Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation
Gastroenterology
(2006) - et al.
Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast
Respir Med
(2001)
National health spending in 2005: the slowdown continues
Health Aff (Millwood)
Cited by (529)
A longitudinal study of distress symptoms and work impairment in immune-mediated inflammatory diseases
2023, Journal of Psychosomatic ResearchThe cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission
2023, The Lancet Gastroenterology and Hepatology
The authors disclose the following: Supported in part by National Center for Research Resources grant 1K12 RR023248-04 (to M.D.K.) and National Institute for Diabetes and Digestive and Kidney Diseases grant 5P30 DK034987 (to M.D.K.).